Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Read on to learn why. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the ...

Value stocks offer good opportunities for long-term investment in 2025, especially for investors who want stability and ...

Franklin Resources trimmed its Pfizer stake by a smidge, selling just 25,315 shares—but when you’ve got over 16 million, ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

StoneX Group clearly didn’t skip leg day—it just bulked up its Pfizer holdings by a massive 43.5% in Q4, scooping up over ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

The global heads of German automakers BMW and Mercedes, as well as chip giant Qualcomm are among foreign business leaders due to meet with Chinese President Xi Jinping this week, two sources said on ...

The stock's dramatic 47% decline from its three-year high has created what I believe is a significant value opportunity. With a historically depressed forward P/E ratio of 8.7, Pfizer stock offers ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful Covid-19 ...